Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Louisiana Patients Could Lose Access to GLP-1 Weight-Loss Drugs as Coverage Vanishes Highlights Louisiana state employees are already prohibited from using GLP-1s for weight loss despite $200 million annual spending on diabetes coverage Over 41 million Americans lost commercial insurance coverage for Wegovy in 2026, with major insurers eliminating coverage nationwide Four states, including California and Pennsylvania, eliminated Medicaid coverage for obesity treatment between October 2025 and January 2026 Louisiana Medicaid provides limited coverage for one non-GLP-1 weight-loss drug but restrictions remain tight Patients face monthly costs ranging from $936 to $1,349 without insurance coverage BATON ROUGE, La
In regulatory speak, this means: significant safety concerns. Compounding pharmacies can no longer legally produce it for human use
found exenatide did not significantly lower DBP compared to insulin glargine [88]
A 2021 retrospective cohort study published in the Journal of Alternative and Complementary Medicine analyzed 347 patients receiving combination lipotropic injections (methionine-inositol-choline plus glutathione-ascorbic acid) alongside structured caloric deficit
US$ 27.51
US$ 27.67
US$ 26.85
